Hope and hype: psychedelic drugs still to prove value in clinical trials
By
Weekly Data
Top 10 deals in the clinical trial operations industry in Q1 2022
| Deal | Value |
|---|---|
| Sanofi and IGM Biosciences | $6250m |
| Sanofi and Exscientia | $5300m |
| Biocon Biologics and Viatris | $3335m |
| Bristol Myers Squibb and Century Therapeutics | $3000m |
| Cinven and Bayer | $2600m |
| Sanofi and Adagene | $2517.5m |
| Samsung Biologics and Biogen | $2300m |
| Bristol Myers Squibb fundraise | $2000m |
| Takeda Pharma and Code Biotherapeutics | $2000m |
| Zinc Merger Sub and Zogenix | $1900m |
Latest Deals
Pharma Technology Focus Magazine
Pharma Technology Focus is free to read on all devices. Subscribe to Pharma Technology Focus and never miss an issue.
Subscribe
GlobalData Reports
